A V Wegst

Are you A V Wegst?

Claim your profile

Publications (3)2.85 Total impact

  • Source
    Article: Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone.
    R G Robinson, G M Blake, D F Preston, A J McEwan, J A Spicer, N L Martin, A V Wegst, D M Ackery
    [show abstract] [hide abstract]
    ABSTRACT: Two hundred and two patients with bone pain from metastatic cancer were treated with 40 microCi/kg of Sr-89. Patients were followed with pain diaries, records of medication taken, sleep patterns, serial bone scans and a Karnofsky Index. One hundred and thirty-seven patients with adequate followup survived at least 3 months, including 100 with prostate and 28 with breast carcinoma. Eighty of the 100 patients with prostate cancer responded, and 25 of the 28 breast cancer patients improved. Ten patients with prostate cancer and five with breast cancer became pain free. Little hematologic depression was noted. Sr-89 kinetic studies showed that strontium taken up in osteoblastic areas remained for 100 days. The tumor-to-marrow absorbed dose ratio was 10:1.
    Radiographics 04/1989; 9(2):271-81. · 2.85 Impact Factor
  • Article: Methods of calculating radiation absorbed dose.
    A V Wegst
    [show abstract] [hide abstract]
    ABSTRACT: The new tumoricidal radioactive agents being developed will require a careful estimate of radiation absorbed tumor and critical organ dose for each patient. Clinical methods will need to be developed using standard imaging or counting instruments to determine cumulated organ activities with tracer amounts before the therapeutic administration of the material. Standard MIRD dosimetry methods can then be applied.
    International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology 02/1987; 14(3):269-71.
  • Article: Treatment of metastatic bone pain with strontium-89.
    R G Robinson, J A Spicer, D F Preston, A V Wegst, N L Martin
    [show abstract] [hide abstract]
    ABSTRACT: We have utilized 89Sr as palliative treatment for bone pain secondary to metastatic cancer in the skeleton of over 200 patients. The best results have been in patients with carcinoma of the prostate (80% response rate) and breast (89%). Results in a small number of patients with a variety of other cell types were not nearly as encouraging. Strontium-89 provides excellent palliation in the management of bone pain secondary to prostate and breast carcinoma.
    International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology 02/1987; 14(3):219-22.
Browse more researchers